Prevention Works is a holistic approach to swine health built on our range of innovative world-class vaccines complemented by:
Our goal is going from prevention to prediction and beyond
The Swine Health content site. Curated for you with love.
“We know that vaccinating can decrease the amount of viruses in the air, so vaccination is a good mechanism to prevent airborne transmission” Swine veterinary consultant Dr. Carmen Alonso in Spain picks out lessons from her detailed studies of air samples inside and outside farms suffering an outbreak of PRRS, influenza A or porcine epidemic diarrhoea --- as well as poultry sites with highly pathogenic avian influenza.
Rutger Jansen
“Our recent work demonstrated the presence of the PCV-3 genome within mild-to moderate histological lesions of aborted fetuses.
In this video Dr. Mike Murtaugh discusses vaccine cross-protection on various PCV2 strains: PCV2a, PCV2b & PCV2d. He also talks about the outbreaks of PCVAD and how correct usage of the vaccine is key.
Prof Joaquim Segalés and Dr Oliver Duran Porcine circovirus type 2 (PCV2) was initially detected in the late 1990s in North America and Europe associated with a post weaning multisystemic wasting syndrome in pigs.
Greg Stevenson
Get the latest news on Swine Health Subscribe to our newsletter
Ingelheim, Germany, 13 December 2016 – Having reached the milestone of 1 billion doses sold since launch, yet another vaccine of Boehringer Ingelheim Animal Health crosses a significant threshold making it one of the leading vaccines for the control of Mycoplasma hyopneumoniae globally(1).
Worldwide over two billion pigs have been protected against Porcine Circovirus Disease using Ingelvac CircoFLEX®
The vaccine contributes to sustainable production and supply of healthy, nutritious pork around the world like no other vaccine1
Boehringer Ingelheim Animal Health has sponsored European PRRS Research Award for the third time
The main aim of the award is to encourage research in the field of PRRS (Porcine Reproductive and Respiratory Syndrome)
Three project proposals receive funding of €25,000 each
Ingelheim, Germany, 26 September 2016 - Veterinarians and farmers across the globe have reached the landmark of protecting one billion sows and pigs against the potentially devastating effects of Porcine Reproductive and Respiratory Syndrome (PRRS) using Ingelvac PRRS MLV ®. The vaccine, which was launched in 1994 in the USA, is currently marketed in 19 countries in Asia, Europe, and North America. It contributes to securing the pigs’ health as well as providing healthy pork for consumers around the world.
During the last fifty years or so, disease control in the pork industry has evolved mainly relying on antimicrobials, vaccines, elimination (depopulation, repopulation, eradication, modified early weaning), and/or regional control depending on the disease.
Pig production has responded to the challenge of increased global demand for pork by a process of consolidation and increased size to capture benefits of economies of scale. Over the last 25 years the swine industry has evolved in order to increase production performance, health and animal wellbeing towards age segregated or multiple site production models. In general, it can be stated that the changes in production systems have produced a positive effect in the health status of pigs by improving the way we raise pigs today.